A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects inTP53
Author:
Affiliation:
1. Medicine; Dartmouth-Hitchcock Medical Center; Lebanon NH USA
2. Medical Oncology; Dana-Farber Cancer Institute; Boston MA USA
Funder
Lymphoma Research Foundation
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13042/fullpdf
Reference122 articles.
1. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia;Badoux;Blood,2011
2. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia;Badoux;Journal of Clinical Oncology,2013
3. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia;Bosch;Journal of Clinical Oncology,2009
4. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features;Bowen;Leukaemia & Lymphoma,2007
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia;Life Sciences;2022-12
2. Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53 mutated B-cell prolymphocytic leukemia: a case report and review of literature;Haematologica;2021-12-23
3. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy;Expert Review of Anticancer Therapy;2021-02-08
4. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents;Current Hematologic Malignancy Reports;2021-01-28
5. Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies;British Journal of Haematology;2020-11-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3